Soleno Therapeutics, Inc. SLNO NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score

51/100

1/7 Pass

SharesGrow Intrinsic Value

Il y a eu 50 transactions d'initiés récentes enregistrées pour Soleno Therapeutics, Inc. (SLNO), dont 23 achats et 22 ventes. Le total des achats d'initiés s'élève à $21.22M et le total des ventes d'initiés à $129.87M.

Les initiés notables ayant une activité récente comprennent Manning Meredith, Huang Michael F., Fulk Jennifer. Les transactions d'initiés peuvent fournir des indications sur la façon dont la direction perçoit la valorisation et les perspectives futures de l'action.

Transactions d'Initiés — SLNO

Date	Nom	Rôle	Type de Transaction	Actions	Prix Moyen	Valeur	Actions détenues
2026-03-27	Manning Meredith	Chief Commercial Officer	Vente Informative	558	$31.72	$17.7K	64,507
2026-03-27	Huang Michael F.	Sr. VP of Clinical Development	Vente Informative	488	$31.72	$15.48K	39,823
2026-03-02	Fulk Jennifer	Officer	Inconnu	-	-	-	-
2026-03-02	Fulk Jennifer	Chief Financial Officer	Attribution de RSU	39,200	-	-	39,200
2026-01-21	Mackaness James H	Chief Financial Officer	Attribution de RSU	32,800	$43.65	$1.43M	32,800
2026-01-21	Anish Bhatnagar	Chief Executive Officer	Attribution de RSU	131,400	$43.65	$5.74M	131,400
2026-01-21	Yen Kristen	See Remarks	Attribution de RSU	11,900	$43.65	$519.44K	11,900
2026-01-21	Manning Meredith	Chief Commercial Officer	Attribution de RSU	32,800	$43.65	$1.43M	32,800
2026-01-21	Hirano Patricia C	See Remarks	Attribution de RSU	11,900	$43.65	$519.44K	11,900
2026-01-21	Norrett Kevin	Chief Business Officer	Attribution de RSU	4,000	$43.65	$174.6K	4,000
2026-01-21	Joshi Manher	Chief Development Officer	Attribution de RSU	4,700	$43.65	$205.16K	4,700
2026-01-21	Huang Michael F.	Sr. VP of Clinical Development	Attribution de RSU	11,900	$43.65	$519.44K	11,900
2025-12-15	Mackaness James H	Chief Financial Officer	Retenue Fiscale RSU	2,013	$49.95	$100.55K	103,163
2025-12-15	Anish Bhatnagar	Chief Executive Officer	Don (Donné)	100,000	-	-	469,456
2025-12-15	Yen Kristen	See Remarks	Retenue Fiscale RSU	904	$49.95	$45.15K	27,239
2025-12-15	Manning Meredith	Chief Commercial Officer	Retenue Fiscale RSU	1,922	$49.95	$96K	43,429
2025-12-15	Hirano Patricia C	See Remarks	Retenue Fiscale RSU	904	$49.95	$45.15K	12,302
2025-12-15	Huang Michael F.	Sr. VP of Clinical Development	Retenue Fiscale RSU	812	$49.95	$40.56K	36,005
2025-11-17	Norrett Kevin	Officer	Inconnu	-	-	-	-
2025-11-17	Norrett Kevin	Chief Business Officer	Attribution de RSU	14,286	-	-	14,286
2025-11-10	Joshi Manher	Officer	Inconnu	-	-	-	-
2025-11-10	Joshi Manher	Chief Development Officer	Attribution de RSU	16,071	-	-	16,071
2025-10-13	Hahn Mark W	Officer	Inconnu	-	-	-	-
2025-10-13	Hahn Mark W	Director	Attribution de RSU	10,046	-	-	10,046
2025-07-01	Hirano Patricia C	See Remarks	Vente Informative	3,830	$82.76	$316.97K	13,206
2025-06-24	Hirano Patricia C	See Remarks	Exercice d'Options (Vente)	266	$44.25	$11.77K	-
2025-06-05	Harris William G	Director	Attribution de RSU	3,991	-	-	19,392
2025-06-05	Pauls Matthew	Director	Attribution de RSU	3,991	-	-	10,491
2025-06-05	Bir Dawn Carter	Director	Attribution de RSU	3,991	-	-	16,991
2025-06-05	Volck Birgitte	Director	Attribution de RSU	3,991	-	-	17,536
2025-06-05	Sinclair Andrew	Director	Attribution de RSU	3,991	-	-	10,491
2025-04-01	Hirano Patricia C	See Remarks	Vente Informative	3,782	$70.11	$265.16K	27,036
2025-03-28	Vivo Opportunity, Llc	10 Percent Owner	Vente Informative	333,557	$70.60	$23.55M	4,458,294
2025-03-28	Pauls Matthew	Director	Vente Informative	5,937	$71.55	$424.8K	6,500
2025-03-28	Hirano Patricia C	See Remarks	Exercice d'Options (Vente)	2,691	$33.60	$90.42K	18,842
2025-03-27	Vivo Opportunity, Llc	10 Percent Owner	Vente Informative	1,100,000	$67.80	$74.58M	4,791,851
2025-03-27	Mackaness James H	Chief Financial Officer	Exercice d'Options (Vente)	5,000	$2.60	$12.98K	-
2025-03-27	Anish Bhatnagar	Chief Executive Officer	Exercice d'Options (Vente)	16,666	$25.05	$417.48K	-
2025-03-27	Yen Kristen	See Remarks	Exercice d'Options (Vente)	4,888	$5.10	$24.93K	2,445
2025-03-27	Manning Meredith	Chief Commercial Officer	Vente Informative	37,000	$67.04	$2.48M	45,351
2025-03-27	Hirano Patricia C	See Remarks	Exercice d'Options (Vente)	6,000	$24.00	$144K	-
2025-03-27	Huang Michael F.	Sr. VP of Clinical Development	Vente Informative	10,000	$70.03	$700.33K	36,817
2025-03-26	Vivo Opportunity, Llc	10 Percent Owner	Vente Informative	400,000	$65.80	$26.32M	5,891,851
2025-01-21	Mackaness James H	Chief Financial Officer	Attribution de RSU	31,000	$49.17	$1.52M	31,000
2025-01-21	Anish Bhatnagar	Chief Executive Officer	Attribution de RSU	115,600	$49.17	$5.68M	115,600
2025-01-21	Yen Kristen	See Remarks	Attribution de RSU	13,800	$49.17	$678.55K	13,800
2025-01-21	Manning Meredith	Chief Commercial Officer	Attribution de RSU	29,200	$49.17	$1.44M	29,200
2025-01-21	Hirano Patricia C	See Remarks	Attribution de RSU	13,800	$49.17	$678.55K	13,800
2025-01-21	Huang Michael F.	Sr. VP of Clinical Development	Attribution de RSU	13,800	$49.17	$678.55K	13,800
2025-01-03	Mackaness James H	Chief Financial Officer	Vente Informative	3,791	$46.18	$175.05K	111,298

■ Informatif — transaction sur marché ouvert (la plus significative) ■ Non informatif (achat) — récompense, exercice d'option, conversion ■ Non informatif (vente) — retenue fiscale, vente à l'acquisition ■ Neutre — don, fiducie, expiration